Insulin resistance is one of the determinants of post-prandial hyperglycaemia. Recently, acarbose, an a-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, has been found to reduce the incidence of cardiovascular disease in patients with impaired glucose tolerance or diabetes. However, the molecular mechanism by which acarbose inhibits cardiovascular events remains unknown. In this study, we examined whether oral administration of acarbose could suppress expression of monocyte chemoattractant protein-1 (MCP-1) in fructose-fed rats, a widely used animal model of insulin resistance. Serum MCP-1 levels were elevated in fructose-fed rats after 4 weeks. Acarbose treatment for 4 weeks reduced the fructose-induced elevation of serum MCP-1 levels. Acarbose treatment for 8 weeks decreased MCP-1 mRNA levels in the aortae of fructose-fed rats. These results suggest that the cardioprotective effects of acarbose could be due, at least in part, to the suppression of MCP-1 expression.
Introduction
Insulin resistance is one of the determinants of post-prandial hyperglycaemia. 1 Several studies have demonstrated that moderate post-prandial hyperglycaemia increases the risk of cardiovascular disease (CVD) in patients who have impaired glucose tolerance (IGT). 2, 3 Furthermore, the Diabetes Intervention Study (DIS) identified post-prandial hyperglycaemia as an independent risk factor for myocardial infarction and all-cause mortality. 4 These observations suggest that post-prandial hyperglycaemia may be a predictive marker of future cardiovascular events in insulinresistant patients. Acarbose is an α-glucosidase inhibitor that delays the absorption of carbohydrates from the K Nakamura, S Yamagishi, T Matsui et al.
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small intestine in the absence of an increase in insulin secretion, thereby suppressing post-prandial increases in plasma glucose. 5 Recently, the Study TO Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial demonstrated that acarbose reduced the development of diabetes and the incidence of CVD and newly diagnosed hypertension in patients with IGT. 6 -8 A meta-analysis of seven long-term studies has also shown that acarbose prevents myocardial infarction and CVD in patients with type 2 diabetes. 9 Furthermore, we have found recently that acarbose improves insulin sensitivity in fructose-fed rats, a widely used animal model of insulin resistance. 10 These findings suggest that inhibition by acarbose of post-prandial hyperglycaemia may be a promising therapeutic strategy for the prevention of CVD in patients with IGT and/or diabetes. However, the molecular mechanism by which acarbose inhibits the incidence of CVD is not fully understood.
Monocyte chemoattractant protein-1 (MCP-1), a chemokine that mediates the recruitment of monocytes to the vasculature, has been reported to play an important role in atherosclerosis. 11, 12 Indeed, circulating MCP-1 levels are associated with traditional risk factors for atherosclerosis, suggesting that MCP-1 may be a novel target for the therapy of atherosclerosis. 13, 14 Therefore, in this study, we examined whether oral administration of acarbose could decrease aortic gene expression and serum levels of MCP-1 in fructose-fed rats. 15
Materials and methods

CHEMICALS
Acarbose was generously provided by Bayer-Pharma (Wuppertal, Germany).
ANIMALS
Male Sprague-Dawley rats, aged 4 weeks (Charles River Breeding Laboratories, Yokohama, Japan), were used in this study. The rats were randomly divided into three groups: (i) control diet, containing 23.6% protein with a vitamin and mineral mixture (360 kcal/100 g) but no fructose (n = 7); (ii) control diet containing 50% fructose (n = 7); and (iii) control diet containing 50% fructose and 0.04% acarbose (a dose of acarbose of approximately 10 mg/day) (n = 7). The animal diets were prepared by Oriental Yeast Co. Ltd (Siga, Japan). Rats were kept at approximately 22 ± 3°C and 50 ± 20% humidity under a 12 h light/12 h dark cycle. Animals were kept in metabolic cages.
After 4 weeks, blood samples were taken from the jugular vein of each rat for measurement of the level of serum MCP-1. A sample of aorta tissue was obtained from each rat at 12 weeks of age (i.e. after 8 weeks of treatment). All animal procedures were conducted according to the guidelines provided by the Kurume University Institutional Animal Care and Use Committee under an approved protocol.
MEASUREMENT OF MONOCYTE CHEMOATTRACTANT PROTEIN-1
Serum MCP-1 levels were measured with an enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, Minnesota, USA) according to the manufacturer's instructions.
QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
Total RNA was extracted from samples of aorta with Trizol ® reagent (Invitrogen, Carlsbad, California, USA) according to the manufacturer's instructions. Real-time quantitative reverse transcription-polymerase chain reaction was performed using SYBR ® green reagent (Applied Biosystems, Foster City, California, USA) according to the manufacturer's instructions. Primers for K Nakamura, S Yamagishi, T Matsui et al.
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MCP-1 and β-actin were as follows: MCP-1 forward primer, 5′-TCTCTTCCTCCACCAC-TATGCA-3′; MCP-1 reverse primer, 5′-GGCTGAGACAGCACGTGGAT-3'; β-actin forward primer, 5′-GTGGCTCTATCCTGGCC-TCA-3′; and β-actin reverse primer, 5′-TGCTGATCCACATCTGCTGG-3′.
STATISTICAL ANALYSIS
All values are mean ± SE. Data were analysed by one-factor analysis of variance to compare group mean values. P-values < 0.05 were considered to be statistically significant.
Results
During the entire study period, all 21 animals used in the study gained weight normally. As shown previously in a study using the same animals, 10 acarbose treatment for 4 weeks improved insulin sensitivity in the fructose-fed rats (data not shown). Serum MCP-1 levels were elevated in the fructose-fed rats, and treatment with acarbose for 4 weeks significantly decreased fructose-induced MCP-1 levels (P < 0.05) ( Fig. 1 ). Oral administration of acarbose for 8 weeks significantly reduced MCP-1 mRNA levels in the aortae of the fructose-fed rats compared with the untreated fructose-fed rats (P < 0.01) (Fig. 2 ).
Discussion
Metabolic syndrome, also called insulin resistance syndrome, is a cluster of coronary risk factors such as high triglyceride levels, low levels of high-density lipoprotein (HDL)cholesterol and hypertension. 16, 17 It is well known that these metabolic abnormalities can be induced in rats by fructose-rich diets. 15 Indeed, we have shown previously that 
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hyperinsulinaemia and hypertriglyceridaemia with lowered HDL-cholesterol levels developed in rats that were fed a high-fructose diet for 4 weeks. 10 In the present study, we confirmed our previous finding that simultaneous treatment with acarbose improves insulin sensitivity in fructose-fed rats. We demonstrate here for the first time that oral administration of acarbose to fructose-fed rats decreases aortic gene expression as well as serum levels of MCP-1. MCP-1 plays an important role in the early phase of atherosclerosis by initiating monocyte recruitment to the vessel wall, 18 and its expression is found to be elevated in human atherosclerotic plaques. 19 The selective targeting of CCR2, the receptor for MCP-1, was shown to decrease atheromatous lesion formation markedly in apolipoprotein E knockout mice. 20 Therefore, our present study suggests that acarbose may protect against atherosclerosis by suppressing MCP-1 overexpression in patients with insulin resistance.
In the present study, we did not clarify the exact molecular mechanism for the suppression of MCP-1 expression by acarbose. However, it is conceivable that acarbose treatment may block oxidative stress generation and subsequently decrease MCP-1 expression in these animals on the basis of the following findings: (i) postprandial hyperglycaemia induces oxidative stress generation via various biochemical pathways; 21 (ii) acarbose treatment has been reported to prevent the enhancement of cardiac ischaemia-reperfusion injury elicited by post-prandial hyperglycaemia by the inhibition of oxidative stress generation; 22 and (iii) there is a growing body of evidence that MCP-1 gene expression is regulated by the redox-sensitive transcription factor nuclear factor (NF)-κB and that serum MCP-1 levels are increased under various oxidative stress conditions. 23 -26 It is well known that a number of pathophysiological stimuli induce endothelial cell activation as a function of oxidative stress-induced signal transduction. 27 -29 Indeed, oxidative stress has been shown to play an important role in gene expression of adhesion molecules, growth factors and pro-inflammatory cytokines, thus being involved in endothelial dysfunction, an initial process of atherosclerosis. 27 -29 Therefore, the findings of our study suggest that acarbose treatment could protect against atherosclerosis in insulin-resistant IGT and/or diabetes patients as a result of its anti-oxidative properties.
